Concepts (223)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Meningitis, Cryptococcal | 12 | 2018 | 79 | 3.75 | Why? |
| Tuberculosis, Meningeal | 5 | 2019 | 100 | 2.30 | Why? |
| Antigens, Fungal | 8 | 2018 | 106 | 2.05 | Why? |
| AIDS-Related Opportunistic Infections | 7 | 2018 | 260 | 1.60 | Why? |
| Cryptococcus | 5 | 2018 | 29 | 1.32 | Why? |
| Mycobacterium tuberculosis | 4 | 2019 | 1164 | 1.23 | Why? |
| Post-Exposure Prophylaxis | 2 | 2020 | 472 | 1.19 | Why? |
| Fluconazole | 4 | 2018 | 145 | 1.02 | Why? |
| Cryptococcus neoformans | 3 | 2017 | 71 | 0.81 | Why? |
| Fetuins | 1 | 2018 | 2 | 0.77 | Why? |
| Vitamin D-Binding Protein | 1 | 2018 | 83 | 0.69 | Why? |
| HIV Infections | 13 | 2018 | 11620 | 0.68 | Why? |
| Histoplasmosis | 1 | 2018 | 83 | 0.67 | Why? |
| Headache | 2 | 2017 | 2257 | 0.63 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 245 | 0.62 | Why? |
| Leukocytosis | 1 | 2018 | 280 | 0.60 | Why? |
| Hydroxychloroquine | 7 | 2021 | 12447 | 0.60 | Why? |
| Urine | 1 | 2018 | 469 | 0.59 | Why? |
| Antifungal Agents | 6 | 2018 | 1828 | 0.49 | Why? |
| Maternal Mortality | 1 | 2017 | 461 | 0.49 | Why? |
| Tuberculosis, Pulmonary | 2 | 2019 | 1171 | 0.44 | Why? |
| Uganda | 8 | 2018 | 1057 | 0.37 | Why? |
| CD4 Lymphocyte Count | 6 | 2018 | 1517 | 0.35 | Why? |
| Refugees | 1 | 2018 | 809 | 0.35 | Why? |
| Membrane Proteins | 1 | 2018 | 1733 | 0.34 | Why? |
| Outpatients | 1 | 2020 | 3417 | 0.33 | Why? |
| Molecular Diagnostic Techniques | 3 | 2019 | 4239 | 0.31 | Why? |
| Immunoassay | 2 | 2018 | 4485 | 0.29 | Why? |
| Double-Blind Method | 3 | 2020 | 5988 | 0.28 | Why? |
| Mortality | 2 | 2017 | 7132 | 0.25 | Why? |
| Treatment Failure | 2 | 2020 | 2106 | 0.24 | Why? |
| Pre-Exposure Prophylaxis | 2 | 2021 | 1138 | 0.22 | Why? |
| Lost to Follow-Up | 2 | 2017 | 79 | 0.22 | Why? |
| Urinary Bladder Neoplasms | 2 | 2018 | 614 | 0.22 | Why? |
| Tropical Medicine | 2 | 2017 | 237 | 0.20 | Why? |
| Cerebrospinal Fluid | 2 | 2018 | 234 | 0.19 | Why? |
| Trypan Blue | 1 | 2018 | 6 | 0.19 | Why? |
| Carcinoma, Merkel Cell | 1 | 2018 | 35 | 0.18 | Why? |
| Somalia | 1 | 2018 | 62 | 0.18 | Why? |
| Sentinel Lymph Node | 1 | 2018 | 35 | 0.18 | Why? |
| Laos | 1 | 2018 | 144 | 0.18 | Why? |
| Immune Reconstitution Inflammatory Syndrome | 2 | 2017 | 66 | 0.18 | Why? |
| Anti-Retroviral Agents | 2 | 2017 | 1099 | 0.18 | Why? |
| Neurofibromatosis 1 | 1 | 2017 | 19 | 0.18 | Why? |
| Hookworm Infections | 1 | 2017 | 16 | 0.17 | Why? |
| Insulin Antibodies | 1 | 2017 | 9 | 0.17 | Why? |
| Antimalarials | 2 | 2020 | 2505 | 0.17 | Why? |
| Calcium-Binding Proteins | 1 | 2018 | 121 | 0.17 | Why? |
| Penile Neoplasms | 1 | 2018 | 97 | 0.17 | Why? |
| Germ-Line Mutation | 1 | 2017 | 86 | 0.17 | Why? |
| Myanmar | 1 | 2018 | 234 | 0.17 | Why? |
| Staining and Labeling | 1 | 2018 | 169 | 0.17 | Why? |
| Refugee Camps | 1 | 2018 | 62 | 0.17 | Why? |
| Cryptococcosis | 1 | 2018 | 97 | 0.17 | Why? |
| Chemokine CCL3 | 1 | 2017 | 103 | 0.16 | Why? |
| Helminths | 1 | 2017 | 60 | 0.16 | Why? |
| HTLV-I Infections | 1 | 2017 | 54 | 0.16 | Why? |
| Adult | 23 | 2021 | 244371 | 0.16 | Why? |
| Zimbabwe | 1 | 2017 | 198 | 0.16 | Why? |
| Cystectomy | 1 | 2018 | 218 | 0.16 | Why? |
| Lymph Node Excision | 1 | 2018 | 362 | 0.15 | Why? |
| Mycobacterium | 1 | 2017 | 143 | 0.15 | Why? |
| Inhalation Exposure | 1 | 2020 | 405 | 0.15 | Why? |
| HIV Seropositivity | 1 | 2017 | 320 | 0.15 | Why? |
| Whole Exome Sequencing | 1 | 2017 | 437 | 0.14 | Why? |
| Meningitis | 1 | 2017 | 163 | 0.14 | Why? |
| Macrophage Activation | 1 | 2017 | 315 | 0.14 | Why? |
| Kenya | 1 | 2018 | 887 | 0.14 | Why? |
| Carcinoma, Transitional Cell | 1 | 2017 | 198 | 0.14 | Why? |
| Sensitivity and Specificity | 4 | 2019 | 22971 | 0.14 | Why? |
| Male | 24 | 2021 | 367725 | 0.13 | Why? |
| Humans | 41 | 2021 | 930598 | 0.13 | Why? |
| Chemotherapy, Adjuvant | 1 | 2017 | 606 | 0.13 | Why? |
| Thailand | 1 | 2018 | 1155 | 0.13 | Why? |
| Coronavirus Infections | 6 | 2021 | 253789 | 0.13 | Why? |
| Ethiopia | 1 | 2017 | 1222 | 0.13 | Why? |
| Gold | 1 | 2017 | 592 | 0.13 | Why? |
| Global Burden of Disease | 1 | 2017 | 531 | 0.13 | Why? |
| Radiotherapy | 1 | 2018 | 608 | 0.12 | Why? |
| Coinfection | 3 | 2018 | 6820 | 0.12 | Why? |
| Blood Glucose | 2 | 2017 | 3642 | 0.12 | Why? |
| Diabetes Mellitus, Type 1 | 2 | 2017 | 1969 | 0.12 | Why? |
| Female | 23 | 2021 | 380317 | 0.12 | Why? |
| Neglected Diseases | 1 | 2017 | 381 | 0.12 | Why? |
| Tuberculosis, Multidrug-Resistant | 1 | 2017 | 433 | 0.12 | Why? |
| Neoplasm Recurrence, Local | 1 | 2018 | 1063 | 0.11 | Why? |
| Prospective Studies | 8 | 2021 | 43301 | 0.11 | Why? |
| Sputum | 1 | 2019 | 1720 | 0.11 | Why? |
| Canada | 2 | 2021 | 6018 | 0.10 | Why? |
| Metal Nanoparticles | 1 | 2017 | 771 | 0.10 | Why? |
| Malaria | 1 | 2020 | 1097 | 0.10 | Why? |
| Bacterial Proteins | 1 | 2019 | 1318 | 0.10 | Why? |
| Interleukin-10 | 1 | 2017 | 1409 | 0.10 | Why? |
| Cancer Care Facilities | 1 | 2018 | 1190 | 0.10 | Why? |
| Carcinoma, Squamous Cell | 1 | 2018 | 902 | 0.10 | Why? |
| Pneumonia, Viral | 5 | 2020 | 243684 | 0.10 | Why? |
| Middle Aged | 13 | 2021 | 270681 | 0.10 | Why? |
| Pandemics | 5 | 2020 | 389249 | 0.10 | Why? |
| Mass Screening | 3 | 2018 | 8005 | 0.10 | Why? |
| Drug Monitoring | 1 | 2017 | 1408 | 0.09 | Why? |
| Income | 1 | 2017 | 1564 | 0.09 | Why? |
| Drug Resistance, Bacterial | 1 | 2018 | 1414 | 0.09 | Why? |
| Perioperative Care | 1 | 2018 | 1329 | 0.09 | Why? |
| Anti-HIV Agents | 2 | 2017 | 2209 | 0.09 | Why? |
| Travel | 1 | 2006 | 7220 | 0.08 | Why? |
| Insect Repellents | 1 | 2006 | 23 | 0.08 | Why? |
| Clinical Protocols | 1 | 2018 | 2734 | 0.08 | Why? |
| Mountaineering | 1 | 2006 | 20 | 0.08 | Why? |
| Prevalence | 3 | 2018 | 25773 | 0.08 | Why? |
| Antiretroviral Therapy, Highly Active | 3 | 2017 | 952 | 0.08 | Why? |
| Bacteremia | 1 | 2018 | 1372 | 0.08 | Why? |
| Bacteria | 1 | 2018 | 1897 | 0.08 | Why? |
| Follow-Up Studies | 3 | 2020 | 17020 | 0.08 | Why? |
| Survival Analysis | 2 | 2017 | 7592 | 0.08 | Why? |
| Diagnostic Tests, Routine | 1 | 2018 | 2643 | 0.08 | Why? |
| Employment | 1 | 2017 | 1754 | 0.08 | Why? |
| ROC Curve | 1 | 2018 | 6024 | 0.08 | Why? |
| Betacoronavirus | 5 | 2020 | 204454 | 0.08 | Why? |
| Young Adult | 6 | 2018 | 93724 | 0.07 | Why? |
| Autoantibodies | 1 | 2017 | 2094 | 0.07 | Why? |
| Biomarkers | 2 | 2019 | 23361 | 0.07 | Why? |
| Skin Neoplasms | 1 | 2018 | 1679 | 0.07 | Why? |
| Water Microbiology | 1 | 2006 | 248 | 0.07 | Why? |
| Nucleic Acid Amplification Techniques | 1 | 2018 | 3388 | 0.07 | Why? |
| Athletic Injuries | 1 | 2006 | 208 | 0.07 | Why? |
| Polymerase Chain Reaction | 1 | 2019 | 6740 | 0.07 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.06 | Why? |
| Diagnosis, Differential | 1 | 2017 | 7220 | 0.06 | Why? |
| Seroepidemiologic Studies | 1 | 2018 | 10017 | 0.06 | Why? |
| Chemoprevention | 1 | 2006 | 585 | 0.06 | Why? |
| Water | 1 | 2006 | 765 | 0.06 | Why? |
| Occupational Exposure | 1 | 2020 | 4742 | 0.06 | Why? |
| Point-of-Care Systems | 3 | 2021 | 2955 | 0.06 | Why? |
| Neoplasm Micrometastasis | 1 | 2018 | 12 | 0.05 | Why? |
| Time Factors | 2 | 2020 | 31397 | 0.05 | Why? |
| Breast Neoplasms | 1 | 2017 | 3633 | 0.05 | Why? |
| Treatment Outcome | 7 | 2020 | 51732 | 0.05 | Why? |
| Case-Control Studies | 1 | 2018 | 17671 | 0.05 | Why? |
| Genes, Neurofibromatosis 1 | 1 | 2017 | 3 | 0.05 | Why? |
| Oncogenes | 1 | 2017 | 23 | 0.04 | Why? |
| Diffusion | 1 | 2017 | 73 | 0.04 | Why? |
| Radiotherapy, Adjuvant | 1 | 2018 | 180 | 0.04 | Why? |
| Penetrance | 1 | 2017 | 121 | 0.04 | Why? |
| Glutamate Decarboxylase | 1 | 2017 | 25 | 0.04 | Why? |
| C-Peptide | 1 | 2017 | 77 | 0.04 | Why? |
| Retrospective Studies | 5 | 2020 | 105322 | 0.04 | Why? |
| Sentinel Lymph Node Biopsy | 1 | 2018 | 173 | 0.04 | Why? |
| Severity of Illness Index | 3 | 2020 | 48226 | 0.04 | Why? |
| CD4-CD8 Ratio | 1 | 2017 | 235 | 0.04 | Why? |
| Hospital Mortality | 1 | 2021 | 22087 | 0.04 | Why? |
| Communicable Disease Control | 1 | 2006 | 29620 | 0.04 | Why? |
| Glucose Tolerance Test | 1 | 2017 | 238 | 0.04 | Why? |
| Global Health | 2 | 2017 | 13911 | 0.04 | Why? |
| Lymphatic Metastasis | 1 | 2018 | 537 | 0.04 | Why? |
| United States | 2 | 2020 | 46150 | 0.04 | Why? |
| Risk Factors | 3 | 2020 | 71621 | 0.04 | Why? |
| Anti-Bacterial Agents | 1 | 2018 | 10083 | 0.04 | Why? |
| Respiration, Artificial | 1 | 2021 | 22116 | 0.04 | Why? |
| Endpoint Determination | 1 | 2017 | 344 | 0.04 | Why? |
| Blood Culture | 1 | 2018 | 308 | 0.04 | Why? |
| Aged, 80 and over | 4 | 2018 | 88759 | 0.04 | Why? |
| Incidence | 1 | 2017 | 25622 | 0.04 | Why? |
| Proportional Hazards Models | 2 | 2017 | 6543 | 0.03 | Why? |
| Diarrhea | 1 | 2006 | 2743 | 0.03 | Why? |
| Intensive Care Units | 1 | 2021 | 29594 | 0.03 | Why? |
| Mental Disorders | 1 | 2017 | 6742 | 0.03 | Why? |
| Survival Rate | 2 | 2018 | 9206 | 0.03 | Why? |
| Neoadjuvant Therapy | 1 | 2017 | 554 | 0.03 | Why? |
| Aged | 6 | 2021 | 215776 | 0.03 | Why? |
| Particle Size | 1 | 2017 | 1052 | 0.03 | Why? |
| Adolescent | 3 | 2017 | 86841 | 0.03 | Why? |
| Zoonoses | 1 | 2006 | 3034 | 0.03 | Why? |
| Lung | 1 | 2021 | 31049 | 0.03 | Why? |
| Lymph Nodes | 1 | 2018 | 1060 | 0.03 | Why? |
| Luminescent Measurements | 1 | 2017 | 924 | 0.03 | Why? |
| Educational Status | 1 | 2017 | 1451 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2018 | 2324 | 0.03 | Why? |
| Antibodies | 1 | 2017 | 846 | 0.03 | Why? |
| Chemokines | 1 | 2017 | 1095 | 0.03 | Why? |
| Linear Models | 1 | 2017 | 1914 | 0.03 | Why? |
| Developing Countries | 1 | 2006 | 4283 | 0.03 | Why? |
| Limit of Detection | 1 | 2017 | 2698 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| Social Class | 1 | 2017 | 1360 | 0.02 | Why? |
| Kinetics | 1 | 2017 | 3238 | 0.02 | Why? |
| Cohort Studies | 3 | 2017 | 36005 | 0.02 | Why? |
| Interviews as Topic | 1 | 2018 | 1952 | 0.02 | Why? |
| Kaplan-Meier Estimate | 1 | 2017 | 4260 | 0.02 | Why? |
| Noninvasive Ventilation | 1 | 2021 | 2329 | 0.02 | Why? |
| Temperature | 1 | 2017 | 2305 | 0.02 | Why? |
| South Africa | 1 | 2017 | 3326 | 0.02 | Why? |
| Viral Load | 2 | 2017 | 15850 | 0.02 | Why? |
| Prognosis | 2 | 2021 | 32490 | 0.02 | Why? |
| Biopsy | 1 | 2014 | 2811 | 0.02 | Why? |
| Asymptomatic Diseases | 1 | 2018 | 3444 | 0.02 | Why? |
| Medication Adherence | 1 | 2014 | 1270 | 0.02 | Why? |
| Pilot Projects | 1 | 2017 | 5182 | 0.02 | Why? |
| Cytokines | 2 | 2017 | 15010 | 0.02 | Why? |
| Ultrasonography | 1 | 2021 | 4409 | 0.02 | Why? |
| Recurrence | 1 | 2014 | 3675 | 0.02 | Why? |
| Rural Population | 1 | 2017 | 2408 | 0.02 | Why? |
| Point-of-Care Testing | 1 | 2017 | 2782 | 0.02 | Why? |
| Polymorphism, Single Nucleotide | 1 | 2017 | 3607 | 0.02 | Why? |
| Patient Care Team | 1 | 2018 | 3556 | 0.02 | Why? |
| Bacterial Infections | 1 | 2018 | 2229 | 0.02 | Why? |
| Models, Biological | 1 | 2020 | 4907 | 0.02 | Why? |
| Animals | 2 | 2017 | 78931 | 0.02 | Why? |
| HIV-1 | 1 | 2017 | 3365 | 0.01 | Why? |
| Risk Assessment | 1 | 2006 | 25439 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| CD4-Positive T-Lymphocytes | 1 | 2017 | 4545 | 0.01 | Why? |
| C-Reactive Protein | 1 | 2017 | 7972 | 0.01 | Why? |
| Vaccination | 1 | 2006 | 19050 | 0.01 | Why? |
| Disease Management | 1 | 2018 | 6841 | 0.01 | Why? |
| Health Personnel | 2 | 2021 | 29646 | 0.01 | Why? |
| Disease Progression | 1 | 2017 | 13580 | 0.01 | Why? |
| Child | 2 | 2017 | 70012 | 0.01 | Why? |
| Brain | 1 | 2014 | 5133 | 0.01 | Why? |
| Biomedical Research | 1 | 2017 | 5270 | 0.01 | Why? |
| Inflammation | 1 | 2017 | 13255 | 0.01 | Why? |
| Infant | 1 | 2017 | 30274 | 0.01 | Why? |
| Child, Preschool | 1 | 2017 | 36283 | 0.01 | Why? |
| Hospitalization | 1 | 2021 | 54280 | 0.01 | Why? |